Background/Aims: Both iron deficiency and chronic inflammation are highly prevalent in patients with chronic kidney disease (CKD). The effect of intravenous iron infusion on mineral metabolism in CKD may be modified by inflammation. Intravenous iron theraphy may reduce peripheral degradation, secretion, clearence of iFGF23 and lead to hypophosphatemia. The aim of the study was to evaluate the effect of intravenous iron on mineral metabolism in CKD patients. Methods: 35 non-dialysis patients with CKD stages 3-5. received 100 mg/24h of ferric oxide saccharated solution for 5 days. Serum calcium (Ca), phosphorus (P), parathormone (PTH), intact-FGF23 (iFGF23), C-terminal-FGF23 (cFGF23), bone alkaline phosphatase (BAP) and high-sensitive CRP were assessed on day 1 and 3 at baseline and 2 hours after each dose administration and once on day 6. Plasma iFGF23 and cFGF23, as well as serum BAP were measured with ELISA and other parameters with standard automated laboratory methods. Results: Serum iFGF23 increased after iv iron on day 1 and 6 (from 268.9±446.5 to 326.3±529.9 on day 1; p=0.05 and to 451.4±601 pg/mL on day 6; p=0.03). cFGF23 was reduced only on day 1 (from 654.3±441.3 to 473.6±414 RU/mL; p=0.016). P concentration decreased significantly two hours after the first iron infusion (from 1.69±0.5 to 1.54±0.35 mmol/l; p=0.003). In following days the changes of cFGF23, P and of other calcium-phosphate metabolism were not significant. Serum CRP correlated neither with iFGF-23 nor cFGF-23. Conclusion: Intravenous iron supplementation may only transiently affect the production and degradation of FGF23 resulting in hypophosphatemia at the commencement of iron therapy. Chronic low-grade inflammation does not seem to play a role in that mechanism.
Introduction
The prevalence of chronic kidney disease (CKD) is increasing in most countries [1] . Anemia is one of the most prevalent complications of chronic kidney disease. The pathogenesis of renal anemia is complex and may include impaired erythropoiesis, reduced red blood cell lifespan, as well as deficiency of iron, which is an essential component of erythropoiesis [2, 3] . Adequate iron stores are a prerequisite for a response to therapy with erythropoiesis-stimulating agents (ESA). Iron deficiency is a common phenomenon among chronic hemodialysis patients [2] [3] [4] and patients with CKD not yet on dialysis who receive ESA. A substantial proportion of patients with CKD and nearly all dialysis patients receiving ESA require iron supplementation [4, 5] .
The treatment of renal anemia usually starts with oral administration of iron preparations. However, iron absorption from the gastrointestinal tract is affected by several factors including medicines such as antacids, tetracyclines, fluoroquinolones, and by the diet [6] . The lingering effect of uremic toxins disrupting the absorption of orally administered drugs is also relevant. In addition, many people do not tolerate oral iron due to gastrointestinal side effects, like nausea, diarrhoea, constipation or abdominal pain [6, 7] . Frequent and persistent undesirable side effects may also contribute to poor patients' cooperation and reduce the utilization of oral iron [7] [8] [9] .
Consequently, iron needs to be administered intravenously in case of severe iron deficiency and failure or intolerance of oral treatment. It is a common practice that the patients on hemodialysis treated with ESA receive intravenous iron supplementation without initial oral therapy [8, 9] .
Another important fact is that an intravenous iron supplementation was found to be much more desirable in economic terms -mainly due to reduced need for ESAs, as well as the reduced need for blood transfusions [10] .
Intravenous iron therapy may also entail a number of unwanted side-effects and longterm consequences including promotion of atherosclerosis, cardiovascular events, infections or cancer [11] [12] [13] [14] .
Additionally, several recent studies have shown that the intravenous iron supplementation can lead to potentially unfavourable changes of mineral metabolism both in healthy humans and in CKD patients [15, 16] . Moreover, the latter group is characterized by the presence of subclinical chronic inflammation. It has been shown that inflammation may play a role in fibroblast growth factor-23 (FGF-23) metabolism, the phosphatonin, which is the main factor that regulates urine phosphate excretion [17, 18] .
There are however some discrepancies between the results of the studies examining that phenomenon mainly due to the interpretation of the results of the assays used to measure different forms of FGF23, i.e. intact FGF23 (iFGF23) and c-terminal FGF23 (cFGF23) [19, 20] . The better understanding of the effect of iron treatment on FGF23 metabolism and its clinical implications seem to be very important.
Materials and Methods
In this single-center prospective interventional study, 35 patients with CKD stages 3 to 5 not yet on dialysis (21 males and 14 females, age 60.1±12.3 years, with estimated glomerular filtration rate (eGFR) 22.9±10.4 mL/min per 1.73 m 2 were recruited. The serum concentration of C-reactive protein was 10.8±10.3 mg/l; range -from 0.1 to 29.5 mg/l.
The baseline characteristics of the study group are provided in Table 1 . The study protocol was approved by the Local Ethics Committee and the written informed consent was obtained from all participants.
Inclusion criteria included CKD stage 3-5 ND (NKF/KDOQI) and Hbg <11 g/dL in at least 2 consecutive measurements in the last 3 months.
The patients after kidney transplantation and those who already started hemodialysis therapy, as well as the patients receiving iron supplementation or ESA therapy any time during 4 weeks before being included to the study were not qualified.
Other exclusion criteria included type 1 and type 2 diabetes, history of intolerance of intravenous iron, active inflammation, age <18 years, liver diseases, and mental illness.
Before the commencement of the study, all the patients underwent screening and qualification procedures based on the criteria listed above.
A detailed physical examinations, as well as basic laboratory tests, were carried out at screening visit. Each patient received an intravenous iron infusion for 5 consecutive days in a form of saccharated ferric oxide complex (Vifor France SA). The doses of 100 mg administered as 40-minute intravenous infusion of 100 ml of 0.9% NaCl [1 vial of iron(III)-hydroxide sucrose complex (Ferri hydroxidum saccharum)] were given in 24-hour intervals.
The patients remained in the ward for the duration of the study. All subjects received a diet prepared by the registered dietician with normal-phosphate, calcium and protein content (phosphorus -750 mg, calcium -700 mg, protein -50 g).
On day 1 and 3, immediately before and two hours after the administration of the iron, blood samples were collected for the measurement of the following blood parameters: FGF-23 including c-FGF23 and iFGF23, PTH, bone alkaline phosphatase (BAP), phosphorus (PO4), and calcium (Ca). All measurements were repeated on day 6.
Blood for the pre-infusion measurements was collected in the morning after an overnight fast. The samples were immediately centrifuged at 3000 rpm at 4 O C for 10 minutes, and the supernatants were frozen at -80 O C for the measurements. Plasma iFGF23 and cFGF23 were measured with ELISA (intact FGF-23, Human 2nd generation and cFGF-23, 2nd generation, TECOmedical, Sissach, Switzerland). Serum bone alkaline phosphate was measured with the ELISA method (TECOmedical group, Sissach, Switzerland).
Serum high-sensitive CRP, calcium, phosphorus, creatinine, iron and plasma PTH were measured using standard automated laboratory methods. 
Statistical analysis
The results are presented as mean ± SD. P value <0.05 was considered statistically significant. The data distribution was checked with the Kolmogorov-Smirnov test. Within-group comparisons were made using the ANOVA for repeated measurements. For categorical variables, the chi-square test or the Fisher exact test were used. Spearman's rank correlation coefficient was calculated to assess the associations between variables. The statistical analysis was performed using Statistica for Windows (version 10PL, StatSoft, Tulsa, OK, USA).
Results
Two hours after the first iron infusion and on day 6 a significant increase of plasma iFGF23 was observed compared to baseline (p=0.05 and p =0.03, respectively) ( Fig. 1.) . Plasma concentration of cFGF23 decreased significantly only after the first iron infusion (p=0.016) (Fig. 1.) . Serum phosphorus decreased significantly on day 1 two hours after the iron infusion (p=0.003) (Fig 1.) . On the following days not only the changes of cFGF23 and phosphorus but also Ca concentration were not significant (Fig 1) .
The changes of serum PTH concentrations were not significant and were as follows: 36.7±94.3 and 34.9±80.9 on day 1, 42.0±103.1 and 27.2±70.1 on day 3 and 32.0±71.6 pmol/l on day 6. BAP concentrations were also unchanged through the study: 24.2±6.4 and 24.3±7.3 on day 1, 24.3±7.6 and 23.9±7.0 on day 3 and 27.0±11.4 U/L on day 6.
A correlation between serum CRP and iFGF-23 were not significant at baseline and in the following days. Plasma cFGF-23 did not also correlate with CRP with the exception of day 3 (r=-0.351; P=0.03). 
Discussion
The main finding of the study was that iron hydroxide sucrose complex IV infusion in non-dialysis CKD patients cause an increase of serum iFGF23 and only short-term changes of cFGF23 and serum phosphate. These effects do not appear to be modified by low-grade inflammation.
The study was designed to further explore the recently postulated impact of intravenous iron therapy on mineral metabolism in CKD patients and to explore possible relations between chronic inflammation and the changes of FGF-23 metabolism after an intravenous iron administration. It has been shown that inflammatory factors may alter the balance of FGF23 production and cleavage, leading to higher circulating active hormone -iFGF23 [21] .
David et al., speculated that a sustained FGF23 overproduction could overwhelm the capacity of FGF23 cleavage apparatus in osteocytes [21] . It was shown that an increased activity of hypoxia inducible factor -1 alpha is one of the mechanisms through which inflammation may stimulate FGF23 transcription [21] .
Phosphate homeostasis is maintained via the bone-kidney endocrine axis that involves PTH, active vitamin D and FGF23. FGF-23 appears to be one of the main determinants of phosphate balance [22] . The potential clinical relevance of iron-induced hypophosphatemia is uncertain, since it often goes unnoticed probably due to a lack of typical clinical symptoms [23] .
In patients with CKD and anemia treated with IV iron, hypophosphatemia is rarely diagnosed, but in the cases of iron deficiency anemia caused by chronic loss of blood in the subjects with normal kidney function its prevalence may reach 70% [24, 25] . However, in a recent study in the patients with anemia associated with the inflammatory bowel disease but without CKD intravenous iron supplementation neither induced any changes of serum FGF23 nor the episodes of clinically significant hypophosphatemia [26] .
The studies have shown that hypophosphatemia induced by intravenous iron administration is apparently mediated by an increase of serum FGF23 what we have also shown in our study. The interpretation of the findings may however depend on the choice of the laboratory method used for the measurement of FGF23.
Circulating FGF23 concentration could be measured using two different commercially available assays, i.e. intact FGF23 (iFGF23) assay and C-FGF23 assay. The iFGF23 assay detects the full-length protein, whereas the C-FGF23 assay binds to epitopes within the C-terminal region of the FGF23 protein and therefore detects both the full-length protein and C-terminal fragments. The full-length iFGF23 protein is considered a biologically active form of FGF23 [27] . The C-terminal fragment is generally regarded as an inactive form [28] . In our study, iFGF23 and cFGF23 were measured in parallel. Despite the highest biological activity of iFGF23 [27] , it was found that the measurement of C-terminal FGF23 might be preferable since that form shows less biological variability compared to iFGF23 [28] .
It is of note that in more recent studies, the use of the assays that detect C-terminal or iFGF23 was found to lead to significant discrepancies in the results, and consequently may have resulted in different clinical interpretations [28] .
Another potential mechanism of increased FGF23 concentration might be tubular injury as reflected by increased serum concentration of annexin -a calcium binding protein expressed abundantly in renal tubules [29] . The role of annexin in the regulation of mineral metabolism is, however, complex since its deficiency caused not only increased FGF23 concentration but also decreased calcitriol and PTH [30] .
We have decided to recruit only non-dialysis CKD patients to our study since most previous studies in the field have been limited to chronic hemodialysis patients [31] .
Iron therapy in our study was continued for six days and patients received a cumulative dose of 600 mg of iron. Each single dose of iron was not larger than 100 mg due to a higher risk of adverse effects [26] .
The treatment period in our data should be long enough to see the changes of FGF-23 and serum phosphate. It is particularly important in case of FGF-23 which serum concentration may significantly change only after a few hours. Christov et al. showed that the significant changes in serum FGF-23 may occur already after 1 hour of acute kidney injury onset with more than tenfold rise during 24 hours [31] .
However, the study of Prats et al. was longer and the changes in serum phosphate persisted for 3 months [15] . That study showed, among others, that a single high dose of IV iron (1000 mg) may lead to significant changes of FGF23 and serum phosphate.
In the study of Wolf et al. a single dose of iron was 1000 mg, but the observation time was 35 days. The laboratory tests were performed at baseline, 24 hours after the beginning of the study, on day 7, 14 and 35 [16] .
In another study the administration of 1500, 2000, 2500 or 3000 mg of iron did not cause an increase of FGF-23 concentration and hypophosphatemia [26] .
Interestingly, despite a much smaller dose of iron in our study there were changes in both serum phosphate and FGF-23.
An advantage of our study was that the patients remained in the ward for the whole duration of the study. That allowed us to control, co-medications and avoid any unnecessary changes of the concomitant therapy.
That also allowed us to control the diet that was prescribed to the patients. The amount of phosphate in the diet was strictly controlled for the duration of the study. Since phosphate intake is the principle factor that stimulates the secretion of FGF23 [32] , any fluctuations in its content in the diet during the iron therapy could lead to improper interpretation of the results. Thus, all meals were prepared by a hospital nutritionist and the amount of phosphorus in the diet was the same in the subsequent days of the study.
In our study we decided to use iron hydroxide III sucrose. Recently published data showed that the risk of hypophosphatemia may be higher with some intravenous iron formulations, e.g. intravenous iron sucrose infusion has been associated with marked hypophosphatemia and even osteomalacia [33] .
In another study the use of ferric carboxymaltose, in non-dialysis patients, Prats et al. showed a reduction of serum phosphate levels that persisted for up to 3 months after iron infusion and it was associated with a decrease of serum FGF23 but there were no changes of other bone metabolism parameters [15] . These results are consistent with ours at least in the short-term, since we did not observe any significant changes of plasma BAP, PTH or serum calcium concentration.
It is noteworthy that in chronic hemodialysis patients , IV low molecular weight iron dextran [34] or saccharate ferric oxide infusion [33] induced an increase in serum FGF23 and a decrease in PTH but without any significant changes of serum phosphate [34, 35] .
Our results are consistent with the study of Wolf et al. that revealed that after IV iron iFGF23 increased. One of the potential mechanisms explaining such the effect was the inhibition of FGF23 degradation in osteocytes leading to a transient increase of iFGF23 and thereby to reduced serum phosphate.
The decrease of cFGF23 might be caused by a reduction of fgf23 transcription caused by iron [16] .
It appears that the different effects of various carbohydrate derivatives of iron preparations on FGF23 are mediated by enzyme involved in the degradation of FGF23, i.e. furin. It may affect cleavage of the secreted, biologically active FGF23 molecule, which results in, among others, inactive cFGF23 fragment.
In contrast to previous studies we have also analyzed the changes of bone alkaline phosphatase -BAP, but no significant effect of iron infusion on this parameter of bone turnover was observed. Our results contrast with an earlier study that revealed that in the presence of hypophosphatemia the activity of alkaline phosphatase increases [36] likely in order to provide higher phosphate supply to bone cells. Our study was probably too short to confirm such the effect.
Moreover, we did not observe any significant changes of PTH and calcium concentration and their concentration remained very stable during the study. These results may also contradict the findings of several other studies where a significant effect of an increased production and secretion of FGF23 on serum PTH was seen and was either phosphate mediated or independent [37, 38] . It seems that our study might have been too short to demonstrate any changes of PTH.
Our study has several limitations. The number of participants was low; however, in other studies in the field a number of subjects was even lower [35, 39] . It is noteworthy that most of those studies were performed in subjects with preserved kidney function [39] or in hemodialysis patients [35] . For example -in Schouten's et al. study one of the exclusion criteria was eGFR less than 60 mL/min./1.73 m 2 [39] . Furthermore, we have not included a reference group of healthy subjects or subjects without iron deficiency. It has already been elegantly shown that iron deficiency by itself may cause the changes of the production and secretion of FGF23 [21, 40] . IV iron supplementation in the healthy population could provide information on the actual impact of iron without the confounding effect of anemia. Another limitation of our study was the lack of the assessment of urinary phosphate excretion.
Conclusion
The effect of intravenous iron supplementation on mineral balance in patients with chronic kidney disease and anemia remains unclear. It seems that additional factors, such as chronic inflammation do not play a role in that mechanism.
Disclosure Statement
The authors declare they have no conflict of interest.
